GVOKE VIALDX Drug Patent Profile
✉ Email this page to a colleague
When do Gvoke Vialdx patents expire, and when can generic versions of Gvoke Vialdx launch?
Gvoke Vialdx is a drug marketed by Xeris and is included in one NDA.
The generic ingredient in GVOKE VIALDX is glucagon. There is one drug master file entry for this compound. Eight suppliers are listed for this compound. Additional details are available on the glucagon profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gvoke Vialdx
A generic version of GVOKE VIALDX was approved as glucagon by FRESENIUS KABI USA on May 8th, 2015.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GVOKE VIALDX?
- What are the global sales for GVOKE VIALDX?
- What is Average Wholesale Price for GVOKE VIALDX?
Summary for GVOKE VIALDX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| What excipients (inactive ingredients) are in GVOKE VIALDX? | GVOKE VIALDX excipients list |
| DailyMed Link: | GVOKE VIALDX at DailyMed |
US Patents and Regulatory Information for GVOKE VIALDX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xeris | GVOKE VIALDX | glucagon | SOLUTION;INTRAVENOUS | 212097-006 | Mar 14, 2025 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for GVOKE VIALDX
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Tetris Pharma B.V | Ogluo | glucagon | EMEA/H/C/005391Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. | Authorised | no | no | no | 2021-02-11 | |
| Eli Lilly Nederland B.V. | Baqsimi | glucagon | EMEA/H/C/003848Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus. | Authorised | no | no | no | 2019-12-16 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for GVOKE VIALDX
See the table below for patents covering GVOKE VIALDX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2016326749 | ⤷ Start Trial | |
| Brazil | 112018005800 | ⤷ Start Trial | |
| Canada | 2999404 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for GVOKE VIALDX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2875043 | 301294 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DASIGLUCAGON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, ZOALS DASIGLUCAGON HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/24/1829 20240725 |
| 2875043 | CR 2024 00043 | Denmark | ⤷ Start Trial | PRODUCT NAME: DASIGLUCAGON ELLER ET FARMACEUTISK SALT ELLER SOLVAT DERAF, SASOM DASIGLUCAGONHYDROCHLORID; REG. NO/DATE: EU/1/24/1829 20240725 |
| 2875043 | 122024000057 | Germany | ⤷ Start Trial | PRODUCT NAME: DASIGLUCAGON IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/24/1829 20240724 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch